Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth

Paediatrics and Child Health

Volumn 16, Issue 9, 2011, Pages 581-589

  Pringsheim, Tamara ^a   Panagiotopoulos, Constadina ^b   Davidson, Jana ^b   Ho, Josephine ^a,c   Belanger, Stacey ^d   Casselman, Lisa ^e   Doja, Asif ^f   Grisaru, Silviu ^a   Jabbal, Rekha ^g   MacKean, Gail ^e   McCrindle, Brian ^h   McLennan, John ^a   Palda, Valerie ^h   Patten, Scott ^a   Pearce, Michelle ^h   Ponesse, Jonathan ^f   Thomas, Roger ^a   Waheed, Waqar ^a   Wilkes, Chris ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e Mental Health Commission of Canada   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

^g ALBERTA CHILDREN'S HOSPITAL   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antipsychotics; Children and adolescents; Drug safety; Extrapyramidal symptoms; Metabolic syndrome

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; SECOND GENERATION ANTIPSYCHOTIC; UNCLASSIFIED DRUG; ZIPRASIDONE;

BODY MASS; CHILD HEALTH; DIABETES MELLITUS; DRUG MONITORING; DRUG SAFETY; ELECTROCARDIOGRAM; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LABORATORY TEST; NEUTROPHIL COUNT; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; SIDE EFFECT; SLIT LAMP; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; WEIGHT GAIN;

EID: 80655125213     PISSN: 12057088     EISSN: None     Source Type: Journal    
DOI: 10.1093/pch/16.9.581     Document Type: Review

References (20)

1. Pringsheim T, Lam D, Patten S. The pharmacoepidemiology of antipsychotic medications in Canadian children. J Child Adolesc Psychopharmacol. (In press)
2. Correll C. Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. Int Rev Psychiatry 2008;20:195-201. (Pubitemid 351489515)
3. Panagiotopoulos C, Ronsley R, Elbe D, Davidson J, Smith D. First do no harm: Promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. J Can Acad Child Adolesc Psychiatry 2010;19:124-37.
4. Blair J, Taggart B. Electrocardiographic safety profile and monitoring guidelines in pediatric psychopharmacology. J Neural Transm 2004;111:791-815. (Pubitemid 38916276)
5. Novartis. Clozaril. East Hanover: Novartis Pharmaceutical Corporation, 2010:1-32.
6. AstraZeneca. Seroquel. Mississauga: Astra Zeneca Canada Inc, 2008:1-50.
7. Harris R, Helfand M, Woolf S, et al. Current methods of the U.S. Preventive Services Task Force. A review of the process. Am J Prevent Med 2001;20(3S):21-35. (Pubitemid 33732964)
8. Guyatt G, Oxman A, Vist G, et al. GRADE: An emerging consensus on rating quality of evidence and strength or recommendations. BMJ 2008;336.
9. Pringsheim T, Lam D, Ching H, Patten S. Metabolic and neurological complications of second generation antipsychotic use in children: A systematic review and meta-analysis of randomized controlled trials. Drug Safety 2011;34:651-68.
10. Pringsheim T, Panagiotopoulos C, Davidson J, Ho J; for the CAMESA guideline group. Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry 2011;20:218-33.
11. Baker J, Olesen L, Sorensen T. Childhood body mass index and the risk of coronary heart disease in adulthood. N Engl J Med 2007;357:2329-37. (Pubitemid 350223387)
12. Mattson N, Ronnemaa T, Juonala M. Childhood predictors of the metabolic syndrome in adulthood. The cardiovascular risk in young finns study. Ann Med 2008;40:542-52.
13. Juonala M, Järvisalo MJ, Mäki-Torkko N, Kähönen M, Viikari JS, Raitakari OT. Risk factors identified in childhood and decreased carotid artery elasticity in adulthood. Circulation 2005;112:1486-93.
14. Pulkki-Raback L, Elovainio M, M. K. Depressive symptoms and the metabolic syndrome in childhood and adulthood: A prospective cohort study. Health Psychology 2009;28:108-16.
15. American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
16. Morato E, Druss B, Harung D. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second generation antipsychotic drugs. Arch Gen Psychiatry 2010;67:17-24.
17. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. J Am Med Assoc 2009;302:1765-73.
18. Anderson G, Scahill L, McCracken J, et al. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 2007;61:545-50. (Pubitemid 46185331)
19. Croonenberghs J, Fegert JM, Findling RL, De Smedt G, Van Dongen S; Group RDBS. Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry 2005;41:64-72. (Pubitemid 40019201)
20. Turrone P, Kapur S, Seeman M, Flint A. Elevation in prolactin levels by atypical antipsychotics. Am J Psychiatry 2002;159:133-5.